Breakthrough virotherapy for cancer

Oncolys BioPharma continuously evolve its business to develop
breakthrough therapy and diagnostics in cancer treatment from early
to late stage, including early detection, loco-regional therapy,
prognostic test, and systemic treatments.
Our mission is to help both patients and physicians through developing
effective and innovating drugs.

News

News Overview
Nov. 2, 2018
News Release
Non-consolidated Financial Results for the Nine Months Ended September 30, 2018[Japanese GAAP]
Nov. 2,2018
Publications
FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
《Outline:The combination treatment of HDAC inhibitor, OBP-801 with FGFR inhibitor, BGJ398 showed the synergistic inhibition of the growth in bladder cancer cells.》
Nov. 2,2018
Publications
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
《Outline:The combination treatment of HDAC inhibitor, OBP-801 with eribulin showed the synergistic inhibition of the growth in TNBC cells.》
Nov. 1,2018
Publications
Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.
《Outline:Relationship between therapeutic response and clinicopathological features using the tissue and liquid biopsy (CTC and cfDNA) from squamous cell lung cancer.》
Oct. 4,2018
Others
We will attend the exhibition of BioJapan 2018 being held at Pacifico Yokohama from October 10 to 12, 2018 (D - 25 booth)
Oct. 2,2018
Publications
The paper relating to virus titration of TelomeScan(OBP-401) and TelomeScan F35(OBP-1101), “A flow cytometry-based method to determine the titer of adenoviruses expressing an extraneous gene”, was published in Biological and Pharmaceutical Bulletin, the official journal of the Pharmaceutical Society of Japan. Permission number「18101004」
Oct. 1,2018
Lecture
9/27/2018 ~ 9/29/2018 "2018 The 77th Annual Meeting of the Japanese Cancer Association" 4 topis regarding telomelysin were announced.
Sep.25, 2018
Publications
The paper relating to TelomeScan(OBP-401), “Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer”, was published in Cancer Science, the official journal of the Japanese Cancer Association.
Aug. 3, 2018
News Release
Non-consolidated Financial Results for the Six Months Ended June 30, 2018[Japanese GAAP]
Aug. 3, 2018
News Release
Announcement of Non-Operating Losses
July. 19, 2018
Lecture
TelomelysinR-Radiation Combination Therapy Clinical Study Data Presented at the 2018 Annual Meeting of JSMO
Jun. 20, 2018
Others
Telomelysin®-Radiation Combination Therapy Data to be Presented at the 16th Annual Meeting of JSMO
May. 23, 2018
News Release
Oncolys Announces In-Licensing Agreement with Stabilitech Biopharma for Novel Virus Stability Platform Technology
May. 17, 2018
Others
Telomelysin-Pembrolizumab Clinical Trial Led by National Cancer Center Hospital East to be Presented in a Poster Session at the 2018 ASCO Annual Meeting in Chicago, USA.
May. 2, 2018
News Release
Non-consolidated Financial Results for the Three Months Ended March 31, 2018[Japanese GAAP]
Mar. 29, 2018
News Release
General Shareholders Meeting 2018 Company Presentation
Mar. 26, 2018
News Release
Oncolys Receives DSMB Approval to Start Higher Dose Patient Cohort 2 in Phase I Clinical Trial for Telomelysin® in Japan
Feb. 23, 2018
News Release
NOTICE OF THE 14TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
Feb. 16, 2018
News Release
Oncolys Invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus
Feb. 15, 2018
News Release
Oncolys Receives Notice of Allowance for EU Patent Expanding OBP-1101 (TelomeScan F35) IP Protection

Pick up contents

  • Pipeline
  • Partnerships
  • IR Information
  • Contact
pagetop